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Abstract
Introduction: This study aimed at evaluating the overall survival (OS) gain associated with human epidermal
growth factor receptor 2 (HER2)-directed therapies in patients with metastatic breast cancer (mBC).
Methods: A bibliographic search was conducted in PubMed and Cochrane databases. Only phase III randomized
controlled trials (RCTs) including HER2-positive (HER2+) mBC patients were included in this review. OS was defined
as time from randomization until the occurrence of death from any cause. Studies have been grouped according to
the line of treatment, i.e., first-line or second-line or beyond.
Results: Nineteen RCTs were eligible for inclusion, of which 12 assessed therapies targeting HER2+ mBC in the
first-line setting. OS improved from 20.3 months in the first RCT (standard chemotherapy; Slamon et al. (N Engl J
Med 344:783–92, 2001)) evaluating HER2-targeting therapies to 48 months in the study of Swain et al. (Lancet
Oncol 14:461–71, 2013), with triple combination of pertuzumab, trastuzumab and docetaxel. Seven RCTs evaluated
the OS of HER2-targeting therapies in the second-line setting and beyond. The OS in second-line setting improved
from 15.3 months (capecitabine; Cameron et al. (Breast Cancer Res Treat 112:533–43, 2008)) to 30.7 months
(trastuzumab emtansine; Verma et al. (N Engl J Med 367:1783–91, 2012)). In the third-line setting, the association of
lapatinib and trastuzumab has demonstrated to improve OS to 4.5 months compared with lapatinib alone
(14 months vs. 9.5 months; Blackwell et al. (J Clin Oncol 30:2585–92, 2012)).
Conclusions: HER2-directed therapies had an undeniable beneficial impact on the OS of patients with HER2+ mBC.
The triple combination of docetaxel, pertuzumab and trastuzumab is associated with a survival extent of more than
4.5 years, compared with a life expectancy of 1.5 years achieved 14 years ago.
Introduction
Breast cancer (BC) is the second most common cancer
worldwide and, by far, the most frequent among women
with an estimated 1.67 million new cases diagnosed in
2012 (25 % of all cancers) (Ferlay et al. [6]). BC is the
fifth cause of death from cancer overall (522,000 deaths)
and it is the most frequent cause of cancer death in
women in less developed regions (324,000 deaths, 14.3 %
of the total) (Ferlay et al. [6]). In the developed countries,
it is the second cause of cancer death (198,000 deaths,
15.4 %), after lung cancer (Ferlay et al. [6]).
In developed countries between 6 and 10 % of women
will have metastatic disease when diagnosed with BC
(Dawood et al. [7]); in developing countries this percent-
age can reach 60 %. Depending on initial stage, tumor
biology, and type of treatment scheme received,
between 30 and 50 % of women with early BC will
relapse (Cardoso et al. [8]).
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The amplification of the human epidermal growth fac-
tor receptor 2 (HER2) is observed in 25 to 30 % of all
BCs (Slamon et al. [1]). Patients with BC with overex-
pression of HER2 have, originally, a poorer prognosis
and shorter overall survival (OS) (Tandon et al. [9];
Slamon et al. [10]).
The development of effective HER2-targeted drugs
is considered a major breakthrough in BC therapy.
Trastuzumab was the first anti-HER2 drug approved
for treatment of HER2-positive (HER2+) metastatic BC, ei-
ther alone or in combination with chemotherapy (Slamon
et al. [1]). This anti-HER2 monoclonal antibody was associ-
ated with a significantly longer time to disease progression,
higher response rate, longer response duration, and im-
proved overall survival (Slamon et al. [1]). During the last
decade, HER2-targeted therapeutic approaches continued
to evolve with a positive impact on the survival of the
women with HER2+ metastatic BC (Dawood et al. [7]).
This study aimed at evaluating the survival gains asso-
ciated with HER2-targeted therapies in patients with
HER2+ metastatic BC.
Methods
Data sources and searches
A bibliographic search was conducted in the PubMed
and in Cochrane Central Register of Controlled Trials
databases (updated October 2015). The search equation
comprised terms referring to HER2+ metastatic BC
(Additional file 1). No language restrictions were ap-
plied. The references lists of systematic reviews were re-
vised in order to identify further studies.
Two reviewers (DM and CA) independently assessed
the titles and abstracts of retrieved articles to determine
trial inclusion. In case of disagreement, the opinion of a
third investigator was sought (BM).
Study selection
Only phase III randomized controlled trials (RCTs) in-
cluding patients with HER2+ metastatic BC have been
analyzed, irrespective of the treatment administered (i.e.,
chemotherapy and/or hormone therapy, chemotherapy
and/or hormone therapy plus HER2-targeted therapy).
Data extraction
Data were abstracted in a standardized format by two inde-
pendent reviewers (DM and CA). The data retrieved from
each publication included study name, bibliographic refer-
ence, publication year, total number of patients allocated to
each treatment arm on the intention-to-treat (ITT) ana-
lysis, characterization of the target population, and efficacy
outcomes. The primary efficacy outcome was OS (defined
as the time from random assignment until death from any
cause), while the secondary outcome was progression-free
survival (PFS, defined as the time from randomization until
objective tumor progression or death) (FDA [11]). We ex-
tracted the median duration (in months) for the outcomes
OS and PFS, based on the ITT analysis. Where outcome
measures were not reported, we contacted the investigators
to provide the data.
Studies were divided according to the line of treat-
ment, i.e., first-line or second-line and beyond.
Data analyses
Data were analyzed using descriptive statistics. Data ana-
lysis was performed using Microsoft Excel 2010 (Micro-
soft Corporation, Redmond, WA, USA).
Results
Figure 1 shows the flow of the search strategy criteria.
The electronic databases searches returned 634 poten-
tially relevant articles; 168 references were duplicates.
After review of the titles and abstracts, 366 references
were refuted and 100 were selected for further evalu-
ation. After the application of the inclusion criteria, 19
RCTs reported in 26 publications were included
(Andersson et al. [12]; Baselga et al. [13]; Baselga et al.
[14]; Guan et al. [15]; Inoue et al. [16]; Johnston et al.
[17]; Kaufman et al. [18]; Robert et al. [19]; Schwartzberg
et al. [20]; Slamon et al. [1]; Swain et al. [2]; Swain et al.
[21]; Valero et al. [22]; André et al. [23]; Blackwell et al.
[24]; Blackwell et al. [5]; Cameron et al. [3]; Cameron et al.
[25]; Geyer et al. [26]; Krop et al. [27]; Pivot et al. [28];
Verma et al. [4]; von Minckwitz et al. [29]; von Minckwitz
et al. [30]; Gelmon et al. [31]; Hurwitz et al. [32]). Review
of published manuscripts’ references did not find any
other eligible studies.
First-line metastatic BC
Twelve phase III RCTs assessed therapies targeting HER2
+ metastatic BC in the first-line setting (Slamon et al. [1];
Swain et al. [2]; Andersson et al. [12]; Baselga et al. [13];
Baselga et al. [14]; Guan et al. [15]; Inoue et al. [16];
Johnston et al. [17]; Kaufman et al. [18]; Robert et al. [19];
Schwartzberg et al. [20]; Swain et al. [21]; Valero et al.
[22]; Gelmon et al. [31]; Hurwitz et al. [32]). The main re-
sults of each RCT are shown in Table 1. Figure 2 presents
the OS (blue) and PFS (red) results for patients diagnosed
with HER2+ metastatic BC receiving first-line treatment,
according to the most effective treatment in each study.
Chemotherapy ± trastuzumab or lapatinib
The first RCT assessing a therapy against HER2 for
metastatic BC that overexpresses HER2 evaluated the
efficacy and safety of standard chemotherapy plus
trastuzumab versus standard chemotherapy alone
(Slamon et al. [1]). In this study, the addition of
trastuzumab to chemotherapy was associated with
longer OS (25.1 vs. 20.3 months, p = 0.046) and
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longer PFS (6.9 vs. 4.5 months, p < 0.001) (Slamon et al.
[1]). Inoue and colleagues evaluated the efficacy of
sequential therapy with trastuzumab monotherapy
followed by trastuzumab plus docetaxel after disease
progression versus upfront combination therapy with
trastuzumab and docetaxel as first-line therapy in
patients with HER2+ metastatic BC. OS and PFS
were significantly longer in the upfront trastuzumab
and docetaxel group (median values not reported for
OS, p = 0.04; median PFS of 14.6 vs. 3.7 months, p < 0.01)
(Inoue et al. [16]). A trial evaluating the efficacy and
safety of lapatinib plus paclitaxel compared to pla-
cebo plus paclitaxel in patients with newly diagnosed
HER2+ metastatic BC showed that the addition of
lapatinib to paclitaxel significantly improved OS and
PFS versus paclitaxel (27.8 vs. 20.5 months, p =
0.0124; 9.7 vs. 6.5 months, p <0.001; respectively)
(Guan et al. [15]).
Chemotherapy + lapatinib versus chemotherapy +
trastuzumab
The MA.31 trial assessed the efficacy of lapatinib versus
trastuzumab combined with taxanes as first-line treat-
ments for HER2+ metastatic BC over 24 weeks, followed
by the same anti-HER2 monotherapy until progression
(Gelmon et al. [31]). Median OS was not observed. Me-
dian PFS was 9.0 months with lapatinib and 11.3 months
with trastuzumab (p = 0.001) (Gelmon et al. [31]).
Hormone therapy ± trastuzumab or lapatinib
The TAnDEM study was the first phase III RCT combining
a hormonal agent and trastuzumab without chemotherapy
Fig. 1 Flow of the search strategy. HER2+ human epidermal growth factor receptor 2 positive, mBC metastatic breast cancer, RCTs randomized
controlled trials
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Table 1 Summary of design and results of studies assessing first-line therapies for the treatment of patients diagnosed with HER2-positive metastatic breast cancer
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Everolimus in trastuzumab-resistant patients
BOLERO-1 Hurwitz
et al. [32]
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(0.73, 1.08),
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AUC area under the curve, CI confidence interval, ECOG-PS Eastern Cooperative Oncology Group performance status, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, HR hazard ratio, LACB
locally advanced breast cancer, LVEF left ventricular ejection fraction, mBC metastatic breast cancer, NA not available, NPLD nonpegylated liposomal doxorubicin, ORR overall response rate, OS overall survival, PD
progression of disease, PFS progression-free survival, PgR progesterone receptor, RECIST Response Evaluation Criteria In Solid Tumors, T1 treatment 1, T2 treatment 2, TTP time to progression












as treatment for HER2/hormone receptor–copositive
metastatic BC (Kaufman et al. [18]). Postmenopausal
women were randomly assigned to anastrozole with or
without trastuzumab until progression; those receiving the
monoclonal antibody in addition to anastrozole experi-
enced a non-statistically significant improvement in OS
(28.5 vs. 23.9 months, p = 0.325), but a statistically signifi-
cant longer PFS (4.8 vs. 2.4 months, p = 0.0016) (Kaufman
et al. [18]). A further study evaluated the effect of adding
lapatinib, a dual tyrosine kinase inhibitor blocking both the
epidermal growth factor receptor and the HER2 receptor,
to the aromatase inhibitor letrozole in women with hor-
mone receptor-positive metastatic BC (Johnston et al.
[17]). The OS and the PFS in the HER2+ population were
of 33.3 months and 8.2 months, respectively, in patients
receiving lapatinib plus letrozole and 32.3 months and
3.0 months, respectively, in patients receiving letrozole
(p = 0.113 and p = 0.019, respectively) (Johnston et al. [17]).
Chemotherapy A + trastuzumab versus chemotherapy B +
trastuzumab
In 2006, the result of a trial evaluating the clinical bene-
fit and safety of the addition of carboplatin to trastuzu-
mab and paclitaxel versus trastuzumab and paclitaxel
alone, reported no difference in OS (35.7 vs. 32.2 months,
p = 0.76), but a significant improvement in PFS (10.7 vs.
7.1 months, p = 0.03) with the inclusion of carboplatin
(Robert et al. [19]). The HERNATA study was designed
to compare docetaxel with vinorelbine, both associated
with trastuzumab, as first-line therapy of HER2+ locally
advanced or metastatic BC (Andersson et al. [12]). In
that trial, the OS and the PFS were of 38.8 months and
15.3 months, respectively, in the vinorelbine plus trastuzu-
mab group and 35.7 months and 12.4 months, respect-
ively, in the docetaxel plus trastuzumab group (p = 0.98
and p = 0.67) (Andersson et al. [12]). In the BCIRG 007
study, patients were randomly assigned to trastuzumab
plus docetaxel or trastuzumab plus carboplatin and doce-
taxel, but no statistically significant differences were found
between groups in OS (37.1 and 37.4 months, respectively;
p = 0.99) and PFS (10.4 vs. 11.1 months, p = 0.57) (Valero
et al. [22]).
Since the addition of trastuzumab to anthracyclines re-
sulted in high incidence of cardiac toxicity in the pivotal
trial conducted by Slamon and colleagues, Baselga and
colleagues conducted a trial of first-line nonpegylated
liposomal doxorubicin plus trastuzumab and paclitaxel
versus trastuzumab and paclitaxel alone in patients
with HER2+ metastatic BC (Slamon et al. [1]; Baselga
et al. [14]). The OS was 33.6 and 28.9 months, re-
spectively (p = 0.083), and the median PFS was 16.1
and 14.5 months, respectively (p = 0.174) (Baselga et al.
[14]). Thus, this trial failed to demonstrate a significant
clinical improvement with the addition of nonpegylated li-
posomal doxorubicin to the trastuzumab and paclitaxel
regimen (Baselga et al. [14]).
Fig. 2 Overall survival (blue) and progression-free survival (red) of patients diagnosed with metastatic breast cancer receiving first-line treatment,
according to the most effective treatment in each study. Results are displayed from the study with lower OS to the study with higher OS. Results
from the study by Inoue et al. [16], Gelmon et al. [31], and Hurwitz et al. [32] are not displayed because OS results were not provided. OS overall
survival, PFS progression-free survival
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Chemotherapy + trastuzumab and pertuzumab
In the CLEOPATRA study, patients with HER2+ meta-
static BC who had not received previous chemotherapy
or biological treatment for their metastatic disease were
assigned to receive pertuzumab plus trastuzumab and do-
cetaxel or placebo plus trastuzumab and docetaxel (Swain
et al. [21]). Median OS in the pertuzumab group was esti-
mated to be 56.5 months, compared to 37.6 months in the
placebo (p < 0.001); the PFS was 18.7 in the pertuzumab
group versus 12.4 months in the placebo group (p < 0.001)
(Swain et al. [2]; Swain et al. [21]).
Everolimus in trastuzumab-resistant patients
The BOLERO-1 trial included women with HER2+,
trastuzumab-resistant, locally recurrent invasive BC un-
amenable to resection with curative intent or metastatic BC
who had not received previous trastuzumab or chemother-
apy for the advanced stage of the disease (Hurvitz et al.
[32]). Patients were randomly assigned to daily everolimus
or placebo plus weekly trastuzumab and paclitaxel.
OS analyses are still in progress. The median PFS was
14.95 months with everolimus and 14.49 months with
placebo (p = 0.1166) in the full population; 20.27 months
with everolimus and 13.08 with placebo in the hor-
mone receptor-negative population (p = 0.0049; did not
cross the protocol-specified threshold of p = 0.0044)
(Hurvitz et al. [32]).
Second-line metastatic BC and beyond
Seven phase III RCTs (11 publications) evaluated therapies
in the second-line setting or beyond (Table 2) (André et al.
[23]; Blackwell et al. [24]; Blackwell et al. [5]; Cameron
et al. [3]; Cameron et al. [25]; Geyer et al. [26]; Krop et al.
[27]; Pivot et al. [28]; Verma et al. [4]; von Minckwitz et al.
[29]; von Minckwitz et al. [30]). Figure 3 presents the OS
(blue) and PFS (red) results for patients diagnosed with
metastatic BC receiving second-line or beyond treatment,
according to the most effective treatment in each study.
Chemotherapy ± trastuzumab or lapatinib
The study by Geyer et al. [26], which included women
with HER2+, locally advanced or metastatic BC that had
progressed after trastuzumab-based therapy, who were
randomly assigned to receive lapatinib plus capecitabine
or capecitabine alone, did not report results on OS
(Geyer et al. [26]), but an updated efficacy analysis
showed that the OS was 15.6 months in patients receiv-
ing lapatinib plus capecitabine and 15.3 months in the
capecitabine alone group (p = 0.177) (Cameron et al.
[3]); while time to progression was of 8.4 months and
4.1 months, respectively (p < 0.001).
The GBG 26/BIG 3–05 phase III study, which included
patients with HER2+ locally advanced or metastatic BC
who had progressed during treatment with trastuzumab,
reported no improvement in OS, but a statistically signifi-
cant improvement of PFS in patients that received capecit-
abine with continuation of trastuzumab compared with
those that received capecitabine alone (24.9 vs.
20.6 months, p = 0.73; 8.2 vs. 5.6 months, p = 0.0338, re-
spectively) (von Minckwitz et al. [29], von Minckwitz et al.
[30]). This trial changed an oncology paradigm since it
showed that continuing trastuzumab beyond progression
(associated with a different anticancer agent) was benefi-
cial (von Minckwitz et al. [29], von Minckwitz et al. [30]).
Chemotherapy + trastuzumab or chemotherapy + lapatinib
Female patients with HER2+ metastatic BC and without
central nervous system metastases were randomly
assigned to receive lapatinib plus capecitabine or trastu-
zumab plus capecitabine in the CEREBEL trial (Pivot et al.
[28]). Patients were required to have received prior
chemotherapy for (neo)adjuvant or metastatic disease.
Nevertheless, approximately 43 % of patients in the
lapatinib plus capecitabine arm and 45 % of patients in
the trastuzumab plus capecitabine arm had not received
prior treatment for the metastatic disease (Pivot et al.
[28]). PFS was longer with trastuzumab plus capecitabine
(8.1 vs. 6.6 months, p = 0.021), with no differences in OS
(27.3 vs. 22.7 months, p = 0.095) (Pivot et al. [28]).
Lapatinib + trastuzumab or lapatinib monotherapy
In the EGF104900 study, patients with heavily pretreated
HER2+ metastatic BC were randomly assigned to receive
lapatinib plus trastuzumab or lapatinib monotherapy as a
third-line anti-HER treatment (Blackwell et al. [5]). Com-
bination lapatinib plus trastuzumab significantly improved
OS and PFS (14 vs. 9.5 months, p = 0.026; and 2.6 vs.
1.9 months, p = 0.010; respectively) (Blackwell et al. [5]).
Trastuzumab emtansine (T-DM1)
Lapatanib plus capecitabine were further compared with
trastuzumab emtansine (T-DM1) in the EMILIA trial that
showed a statistically significant improvement of OS and
PFS in patients treated with the latter regimen (25.1 vs.
30.9 months and 9.6 vs. 6.4 months, respectively, with
p < 0.001 for both end points) (Verma et al. [4]).
In the TH3RESA trial patients with HER2+ unresect-
able locally advanced or recurrent BC or metastatic BC
who had been treated with two or more HER2-directed
regimens, including trastuzumab and lapatinib, were
randomized to receive T-DM1 or treatment of physi-
cian’s choice (Krop et al. [27]). A trend favoring T-DM1
was observed on OS (p = 0.0034), but the stopping
boundary was not crossed. PFS was significantly im-
proved with T-DM1 (median 6.2 months vs. 3.3 months;
p < 0.001) (Krop et al. [27]).
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Table 2 Summary of design and results of studies assessing second-line or beyond therapies for the treatment of patients diagnosed with HER2-positive metastatic breast cancer
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Chemotherapy + trastuzumab or chemotherapy + lapatinib
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Lapatinib 1250 mg/
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Table 2 Summary of design and results of studies assessing second-line or beyond therapies for the treatment of patients diagnosed with HER2-positive metastatic breast cancer
(Continued)
HER2-positive advanced breast
cancer previously treated with
trastuzumab and a taxane
1000 mg/m2 twice a
day on days 1–14 for







TH3RESA Krop et al. [27] 2014 Women (≥18 years, LVEF ≥ 50 %,
ECOG-PS 0–2) with progressive
HER2-positive advanced breast
cancer who had received two or
more HER2-directed regimens in
the advanced setting, including
trastuzumab and lapatinib, and











Everolimus in trastuzumab-resistant patients
BOLERO-3 André et al. [23] 2014 Women with HER2-positive,
trastuzumab-resistant, advanced
breast carcinoma who had
previously received taxane
therapy
Daily everolimus (5 mg/day)
plus weekly trastuzumab






PFS 284 285 NA NA NA 7.00 5.78 0.78
(0.65, 0.95),
p = 0.0067
CI confidence interval, CNS central nervous system, ECOG-PS Eastern Cooperative Oncology Group performance status, HER2 human epidermal growth factor receptor 2, HR hazard ratio, LVEF left ventricular ejection
fraction mBC metastatic breast cancer, NA not available, NYR not yet reached, OS overall survival, PD progression of disease, PFS progression-free survival, T1 treatment 1, T2 treatment 2, T-DM1 trastuzumab
emtansine,TTP time to progression
aCEREBEL was included in the list of studies assessing second-line or beyond therapies because patients were required to have received prior chemotherapy for (neo)adjuvant or metastatic disease, according to the
inclusion criteria of the study. However, it should be noted that nearly 43 % of patients in the lapatinib plus capecitabine arm (117 of 271 patients) and 45 % of patients in the trastuzumab plus capecitabine arm












Everolimus in trastuzumab-resistant patients
The BOLERO-3 trial included women with HER2+,
trastuzumab-resistant, advanced BC who had previously
received taxane therapy (André et al. [23]). Patients were
randomly assigned to daily everolimus plus weekly tras-
tuzumab and vinorelbine or to placebo plus trastuzumab
and vinorelbine. OS was not mature and median PFS
was 7 months with everolimus and 5.8 months with pla-
cebo (p = 0.0067) (André et al. [23]).
Discussion and conclusions
The advances in early diagnosis and adjuvant pharmaco-
logical therapy have led to a decrease in mortality rates
from BC in developed countries (Cardoso et al. [8]).
Nonetheless, the prevalence of metastatic BC is still
high. Many women live with the disease for several
years, but there is, however, a lack of accurate data for
this condition since most cancer registries do not cap-
ture relapses (Cardoso et al. [8]). Metastatic BC is not
considered curable and the treatment goal includes im-
proving patients’ quality of life and prolonging survival
as much as possible (Cardoso et al. [8]).
In the early 1990s the median OS of patients diagnosed
with metastatic BC was only 14 months (Chia et al. [33]).
The introduction of more efficacious therapies has sub-
stantially improved the prognosis of these patients. The
addition of HER2-targeted therapies to standard treat-
ments is associated with marked improvement of OS in
patients with metastatic BC. The first approved HER2-
directed inhibitor, trastuzumab, led to an OS prolongation
of 5 months when added to chemotherapy (Slamon et al.
[1]), and became the standard of care in first-line treat-
ment (Cardoso et al. [8]). The addition of lapatinib to pac-
litaxel also results in a prolongation of 7 months of OS
compared with paclitaxel alone, as well as the prolonga-
tion of PFS (Guan et al. [15]). More recently, the MA.31
trial provided an answer to a relevant clinical question
through a head-to-head comparison between trastuzumab
and lapatinib (both combined with taxanes) as first-line
treatments for HER2+ metastatic breast cancer (Gelmon
et al. [31]). Compared to trastuzumab, lapatinib was asso-
ciated with a shorter PFS and a worse safety profile, with
increased diarrhea, appetite loss, social functioning, and
skin rash (Gelmon et al. [31]). These results support the
use of trastuzumab over lapatinib in patients with
treatment-naïve HER2+ metastatic breast cancer, and have
implications for clinical practice (Gelmon et al. [31]).
Other therapeutic combinations were evaluated in
clinical trials, but not all led to the prolongation of pa-
tients’ survival. The addition of trastuzumab to the hor-
monal agent, anastrozole, was not associated with an
increase of OS, despite an increase of 2.4 months in
PFS, when compared with anastrazole monotherapy
(Kaufman et al. [18]). The lapatinib plus letrozole com-
bination increased PFS by 5 months when compared
with letrozole monotherapy, but both regimens had
Fig. 3 Overall survival (blue) and progression-free survival (red) of patients diagnosed with metastatic breast cancer receiving second-line treat-
ment, according to the most effective treatment in each study. Results are displayed from the study with lower OS to the study with higher OS.
Results from TH3RESA and BOLERO-3 are not displayed because OS results were not provided. GBG 26/BIG 03–05, German Breast Group 26/Breast
International Group 03–05 study. OS overall survival, PFS progression-free survival
Mendes et al. Breast Cancer Research  (2015) 17:140 Page 11 of 14
similar OS (approximately 33 months) (Johnston et al.
[17]). Adding carboplatin to trastuzumab and taxane did
not extend OS and was associated with increased rates
of neutropenia and thrombocytopenia (Robert et al. [19];
Valero et al. [22]). The BOLERO-1 trial showed that the
addition of everolimus to trastuzumab and paclitaxel did
not result in an improvement of PFS in patients with
HER2+ advanced breast cancer (Hurwitz et al. [32]); a
clinically important prolongation of PFS (7.2 months)
was only seen with everolimus (versus placebo) when
the analysis was restricted to hormone receptor-negative
patients, but even so the p value did not achieved the
prespecified criteria for statistical significance (Hurwitz
et al. [32]). Further, everolimus was associated with an
increased risk for serious adverse events, such as neutro-
penia, leucopenia, anemia, febrile neutropenia, stoma-
titis, and fatigue (Hurwitz et al. [32]). In all these studies
evaluation of tolerability and quality of life is as relevant
as efficacy results.
Dual HER2 inhibition with trastuzumab and pertuzu-
mab, a HER2-targeted humanized monoclonal antibody
that inhibits dimerization, was more active than single in-
hibition with trastuzumab (Swain et al. [2]). This thera-
peutic combination prolonged patients’ survival, as well as
PFS across all predefined subgroups. In the CLEOPATRA
study, this led to an unprecedented PFS of 18 months and
median OS of almost 5 years (Swain et al. [2]). Caution
however is needed when extrapolating these results to
current patient populations since only 10 % of patients
from this trial had received prior chemotherapy with or
without adjuvant or neoadjuvant trastuzumab.
HER2-targeted therapies have also demonstrated effi-
cacy in the treatment of metastatic BC in the second-line
setting. When compared to lapatinib plus capecitabine, T-
DM1, an antibody-drug conjugate of trastuzumab and the
chemotherapy drug DM1 (emtansine), extended the OS
for almost 6 months in patients who had previously
received trastuzumab and a taxane (Verma et al. [4]).
Additionally, patients treated with T-DM1 experienced
less toxicity. Similarly, the addition of everolimus to tras-
tuzumab and vinorelbine in patients with trastuzumab-
resistant and taxane-pretreated HER2+ advanced BC was
associated with an improvement in PFS in this population.
However, the addition of everolimus was associated with a
high incidence of serious adverse events, exhibiting a simi-
lar safety profile to that seen in the BOLERO-1 trial
(André et al. [23]). Beyond the second-line setting, a study
demonstrated that treatment with dual HER2 blockade
lapatinib plus trastuzumab improved OS when compared
with lapatinib (Blackwell et al. [5]). However, treatment
with lapatinib plus trastuzumab was associated with
higher rates of treatment discontinuation and toxicity.
More recently, the benefit of T-DM1, mainly on PFS, was
also demonstrated in patients with HER2+ metastatic BC
who have previously received trastuzumab and lapatinib
(Krop et al. [27]).
Patients treated with trastuzumab have higher risk of
cardiotoxicity, mainly asymptomatic left ventricular sys-
tolic dysfunction or congestive heart failure (Slamon
et al. [1]; Seidman et al. [34]). Congestive heart failure
was detected as a safety signal late in the development
of the drug (Seidman et al. [34]). Yet, the rates of cardiac
dysfunction were greatest when trastuzumab was admin-
istered concomitantly with anthracyclines, and the most
frequent events were asymptomatic declines in left ven-
tricular ejection fraction (Seidman et al. [34]; Morris and
Hudis [35]). Evidence suggests that trastuzumab’s cardio-
toxicity is, however, uncommon and generally reversible
(Morris and Hudis [35]; Procter et al. [36]; de Azambuja
et al. [37]). In order to minimize the risk, all candidates
for treatment with trastuzumab must undergo a baseline
cardiac assessment, as well as regular (every 3 months)
assessments during treatment, in particular those who
have been previously exposed to anthracyclines or with
risk factors for cardiac events. Despite this small cardiac
iatrogenic potential, in the majority of patients with
HER2+ metastatic BC, the risk of cardiac dysfunction is
justified given the improvement in OS associated with
trastuzumab (Seidman et al. [34]). Moreover, the most
recently developed HER2-targeted therapeutic alterna-
tives have been associated with relatively low rates of
cardiovascular events (Verma et al. [4]).
Another safety issue is the, apparently, high rate of central
nervous system metastases in patients receiving adjuvant
trastuzumab, raising the question whether this treatment
could predispose for central nervous system recurrence
(Yin et al. [38]). A prospective, observational study of
HER2+ metastatic BC patients concluded that the use of
trastuzumab, chemotherapy, and surgery following central
nervous system metastases were each associated with lon-
ger survival (Brufsky et al. [39]). Furthermore, a retrospect-
ive study found that anti-HER2 treatment is associated with
longer time to occurrence of brain metastases when given
before brain metastases diagnosis and with survival benefit
when given after brain metastases (Yap et al. [40]). Findings
from the CEREBREL clinical trial demonstrated no differ-
ence in the incidence of brain metastasis as a first site of
progression between lapatinib plus capecitabine and trastu-
zumab plus capecitabine (Pivot et al. [28]). The most likely
explanation for the data is that the beneficial effect of tras-
tuzumab on systemic disease extends the survival of pa-
tients to such a degree that central nervous system
metastases became clinically evident (Dawood et al. [41];
Yin et al. [38]).
In clinical practice different combinations than those
evaluated in clinical trials may be used, assuming that
the benefit of trastuzumab is the same regardless of its
partner agent (Pegram et al. [42]; Pegram et al. [43];
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Harris et al. [44]). Only a small number of HER2 com-
bination therapies have been evaluated in RCTs, as it
was noted in a previous meta-analysis (Harris et al.
[44]), but it would be practically and economically un-
feasible and unrealistic to perform a phase III trial to
evaluate all possible combinations. It is now unethical to
perform a study evaluating the addition of an anti-HER2
agent to a given cytotoxic or combination of cytotoxic
agents versus not, the only design that would indeed as-
sess the value of the different combinations. One can
only compare between different combinations. Further-
more, the development of new anti-HER2 agents and
the potential of dual or even triple blockade raises other
possibly more relevant questions to test. The optimal se-
quencing of HER2-targeted therapies across multiple
lines of treatment is of utmost importance due to the in-
creasing number of available drugs (Verma et al. [4]).
There are several other studies evaluating different
combinations of cytotoxic and anti-HER2 agents. How-
ever, such studies usually include a limited number of
patients and do not report on OS. Therefore we chose
to select only phase III RCTs since this design is less
susceptible to bias, providing the highest level clinical
and statistical evidence (Straus et al. [45]).
HER2-targeted therapies have an undeniable favorable
impact in the outcome of patients with HER2+ meta-
static BC. Integration of trastuzumab led to about
6 months benefit in OS. More recently, T-DM1 after
trastuzumab led to a further 6 months benefit in OS.
HER2 dual blockade with pertuzumab and trastuzumab
is associated with a survival extension to more than
4.5 years (Swain et al. [2]). Since 2001, comparing the re-
sults of the clinical trial of Slamon and colleagues evalu-
ating the addition of trastuzumab to chemotherapy,
there has been an increase in OS of 2.5 years with anti-
HER2 drugs (Slamon et al. [1]). Survival improvements
have also been noted for the second- and third-line ther-
apies. Once a poor prognosis disease, HER2+ advanced
BC has now a wide range of therapeutic options that sig-
nificantly increased the OS of patients and has become
the subtype of metastatic BCs with the longest medium
survival, similar to luminal breast cancers.
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